Molecular Cancer

Papers
(The median citation count of Molecular Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives746
Circular RNA: metabolism, functions and interactions with proteins550
The potential role of RNA N6-methyladenosine in Cancer progression512
mRNA vaccine for cancer immunotherapy452
Targeting STAT3 in Cancer Immunotherapy437
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions422
The cancer metabolic reprogramming and immune response402
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance381
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects372
Natural killer cells in cancer biology and therapy344
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma292
Glioma targeted therapy: insight into future of molecular approaches285
Exosomes as a new frontier of cancer liquid biopsy281
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis279
Targeting TGF-β signal transduction for fibrosis and cancer therapy257
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy252
Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis252
Exosome-based immunotherapy: a promising approach for cancer treatment250
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities248
G-quadruplexes: a promising target for cancer therapy246
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments243
Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation240
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target233
PARP inhibitor resistance: the underlying mechanisms and clinical implications231
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes227
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities226
RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner223
The role of m6A RNA methylation in cancer metabolism214
CircRNA inhibits DNA damage repair by interacting with host gene197
The role of ubiquitination and deubiquitination in cancer metabolism194
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc191
mRNA vaccine: a potential therapeutic strategy186
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer183
Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance180
Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies179
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments179
Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells173
Mechanism of RNA modification N6-methyladenosine in human cancer171
The role of N6-methyladenosine (m6A) modification in the regulation of circRNAs171
mRNA therapeutics in cancer immunotherapy169
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine167
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling164
Long noncoding RNAs: functions and mechanisms in colon cancer164
Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer162
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1159
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer153
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer152
m6A modification: recent advances, anticancer targeted drug discovery and beyond149
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer147
Lung cancer immunotherapy: progress, pitfalls, and promises144
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer144
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook141
Cuproptosis: mechanisms and links with cancers136
Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis135
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer135
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer134
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer134
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring131
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2131
Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology130
cGAS-STING pathway in cancer biotherapy127
Cancer associated-fibroblast-derived exosomes in cancer progression127
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer126
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer125
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3122
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation122
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling120
Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression120
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy118
Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis113
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit106
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy106
CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc106
circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer106
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer105
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis103
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing101
RETRACTED ARTICLE: CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p100
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC100
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM98
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy98
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis97
DDX3X: structure, physiologic functions and cancer97
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer96
Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma95
Proteolysis-targeting chimeras (PROTACs) in cancer therapy95
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab94
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development93
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments93
LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression91
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition91
Clinical and immunological effects of mRNA vaccines in malignant diseases90
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer90
Non-coding RNAs regulation of macrophage polarization in cancer89
Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer89
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway88
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer87
Circular RNA circCORO1C promotes laryngeal squamous cell carcinoma progression by modulating the let-7c-5p/PBX3 axis86
Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis86
Targeting the RNA m6A modification for cancer immunotherapy85
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances84
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development83
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms82
The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway81
Insights into N6-methyladenosine and programmed cell death in cancer81
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression80
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis80
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer80
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study80
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy79
CircRNAs: biogenesis, functions, and role in drug-resistant Tumours79
Targeting the tumor stroma for cancer therapy78
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy78
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction77
Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin76
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy76
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma75
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification75
Proteomics technologies for cancer liquid biopsies75
CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability74
Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?74
Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications73
Advancements in nanoparticle-based treatment approaches for skin cancer therapy73
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review72
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer72
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression71
Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2′-O-methylation via NOP58 recruitment in colorectal cancer71
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma71
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing70
Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis70
CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway70
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer68
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis68
Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling67
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression66
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF266
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications66
Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma65
Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling65
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer65
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer65
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies65
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p65
ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma64
CircRNAs in anticancer drug resistance: recent advances and future potential64
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis63
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential63
Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types62
β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer62
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment62
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma62
Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO262
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors61
Targeting KRAS mutant cancers: from druggable therapy to drug resistance61
Delivery of cancer therapies by synthetic and bio-inspired nanovectors61
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p60
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy60
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer59
m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling59
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer59
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer58
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma58
Histone citrullination: a new target for tumors57
Potential clinical utility of liquid biopsies in ovarian cancer57
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions57
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma57
CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma55
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer55
The role and application of small extracellular vesicles in gastric cancer55
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway55
The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer54
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades53
A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F353
Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing53
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy53
The potential roles of exosomes in pancreatic cancer initiation and metastasis53
Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis52
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p52
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin52
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes52
The journey of CAR-T therapy in hematological malignancies52
The involvement of exosomes in the diagnosis and treatment of pancreatic cancer51
A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer51
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy51
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation51
RNA-based therapies: A cog in the wheel of lung cancer defense51
Circular RNAs’ cap-independent translation protein and its roles in carcinomas50
CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner50
Clinical significance of FBXW7 loss of function in human cancers49
CD39/CD73/A2AR pathway and cancer immunotherapy49
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma49
Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling49
A clinician’s handbook for using ctDNA throughout the patient journey49
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC49
Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis49
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer48
circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling48
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis48
The functional roles of the circRNA/Wnt axis in cancer48
Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA48
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses47
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells47
mRNA in cancer immunotherapy: beyond a source of antigen47
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer46
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation46
Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients46
Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas45
Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer45
NK cells and solid tumors: therapeutic potential and persisting obstacles45
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion45
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication44
Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer44
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance44
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers43
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA43
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance43
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma43
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer43
Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer43
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma43
Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer42
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis42
CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis42
Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM142
Tumor-suppressive circRHOBTB3 is excreted out of cells via exosome to sustain colorectal cancer cell fitness41
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression41
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma41
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers41
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer41
Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP1040
Regulatory cells and the effect of cancer immunotherapy40
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors40
Molecular mechanisms of tumor resistance to radiotherapy40
The intersection of COVID-19 and cancer: signaling pathways and treatment implications40
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges40
Nonsense-mediated RNA decay and its bipolar function in cancer40
Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer40
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma40
CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity39
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy39
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions39
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers39
Clinical considerations for the design of PROTACs in cancer39
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma38
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer37
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL237
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac137
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma37
Gold nanoparticles and gold nanorods in the landscape of cancer therapy37
Clinical application and detection techniques of liquid biopsy in gastric cancer36
0.086558103561401